Novo and Celgene will retain shares in the cancer therapy developer, which floated at the upper end of its range and which now has a $600m market cap.
The antibody-based drug developer, which counts WuXi AppTec, Fosun, Sinopharm and Humanwell as investors, has floated in a $126m offering.
Slack Fund and Citi Ventures have reinvested in the communications software developer through a round that lifted its overall funding to $175m.
Yahoo Japan and Alphabet-backed Fractyl aims to make one of its proposed products a cornerstone therapy for type 2 diabetes, and has now raised about $270m in total.
The application management platform developer boosted its overall funding to $86m in a round led by Rakuten Capital.
The Salesforce and Plante Moran-backed customer management software producer plans to make strategic acquisitions with the series C proceeds.
Several companies operating in the digital asset and cryptocurrency markets have invested in a series C round for the decentralised exchange platform operator.
Behavioural health platform developer Brightline captured $72m in a round led by GV, while Gopuff is set to buy Siemens and ST-backed mobility software producer RideOS.
The GlaxoSmithKline and Celgene-backed immunotherapy developer has floated in the middle of its range on the Nasdaq Global Market.
Alphabet unit GV and the Deutsche Telekom-backed DTCP both invested in the graph database software provider at a valuation topping $2bn.
GCV provides the global corporate venturing community and their ecosystem partners with the information, insights and access needed to drive impactful open innovation. Across our three services - News & Analysis, Community & Events, and the GCV Institute - we create a network-rich environment for global innovation and capital to meet and thrive. At the heart of our community sits the GCV Leadership Society, providing privileged access to all our services and resources.
